Results 41 to 50 of about 1,217,759 (290)
Frontiers in Immunology, 2022 IntroductionPrevious studies have shown a reduction in the effectiveness of primary COVID-19 vaccination in patients with rheumatic diseases. However, limited data is available regarding the effectiveness of the COVID-19 vaccine booster dose, especially ...
Jakub Wroński +14 more
doaj +1 more source
Effectiveness of mRNA booster doses against the omicron variant
The Lancet Infectious Diseases, 2022 Since its emergence in November, 2021, the omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly spread and quickly overtaken the delta (B.1.617.2) variant as the most common cause of infection.1 Due to numerous spike mutations, the omicron variant showed increased transmissibility and reduced neutralisation by antibodies from prior infections compared
Hadeel T, Zedan, Nasrallah, Gheyath K
openaire +4 more sources
, 2023 The Centers for Disease Control and Prevention recommends a COVID-19 vaccine booster dose for all persons >18 years of age. We analyzed data from the National Immunization Survey–Adult COVID Module collected during February 27–March 26, 2022 to assess ...
Kushagra Vashist +12 more
core +1 more source
, 1930 Digital reproduction of microfilmed articles and Nellie\u27s Nook sections of The Booster, a Pittsburg High School publication, from the years 1930-1949.https://digitalcommons.pittstate.edu/nellydonpubs/1002/thumbnail ...
The Booster,
core +1 more source
Hib IgG persistence following early booster dose [PDF]
Archives of Disease in Childhood, 2005 A diphtheria/tetanus/acellular pertussis– Haemophilus influenzae type b vaccine (DTaP–Hib), introduced to the UK in 1999, was associated with poor primary Hib responses1 and a resurgence of Hib disease in the population.2 Consequently, in 2003, the UK Department of Health undertook a campaign to immunise children aged 6 months–4 years with an ...
M H, Slack +6 more
openaire +2 more sources
Association Between the “We Can Do This” Campaign and COVID-19 Booster Uptake, U.S., 2021–2022
AJPM FocusIntroduction: Monovalent COVID-19 boosters lower the risk of COVID-19 disease, infection, hospitalization, and death. This study examined associations between exposure to a booster public education campaign (the booster campaign) and the increases in ...
Benjamin Denison, MA, PhD +10 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed ...
Juliana Park +11 more
doaj +1 more source
Disparities in COVID-19 Vaccination Booster Coverage among Healthcare Personnel (HCP) in Urban, Suburban, and Rural Long-Term Care Facilities (LTCF), National Healthcare Safety Network (NHSN), United States, January 2022 – March 2022 [PDF]
As of March 2022, only 47% of healthcare personnel (HCP) in U.S. long-term care facilities (LTCFs) have received a COVID-19 booster dose, despite having access to the booster two months before the general population.
Segovia, George E.
core +1 more source
The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease [PDF]
, 2015 Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer).
Peter Pemberton-Ross +5 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source